PDCD1 and cancer: The blockade of PD-1 stands as a cornerstone in cancer immunotherapy, with Pembrolizumab (Keytruda), a potent humanized monoclonal anti-PD-1 antibody, undergoing rigorous exploration across a broad spectrum of malignancies (52, 53).